Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 110 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BeyondSpring Inc | BYSI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.02 | -0.87% | 2.27 | 07:10:52 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.29 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 3 | 110 | - | 0.6534 - 4.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:10:52 | 5 | $ 2.34 | USD |
BeyondSpring Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 89.13M | 38.92M | - | 1.35M | -33.28M | -0.86 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BeyondSpring News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BYSI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.80 | 2.379 | 1.79 | 2.01 | 83,202 | 0.47 | 26.11% |
| 1 Month | 3.65 | 3.69 | 1.76 | 2.61 | 105,763 | -1.38 | -37.81% |
| 3 Months | 0.9998 | 4.00 | 0.97 | 2.77 | 238,594 | 1.27 | 127.05% |
| 6 Months | 1.03 | 4.00 | 0.7777 | 2.43 | 136,002 | 1.24 | 120.39% |
| 1 Year | 1.05 | 4.00 | 0.6534 | 1.99 | 98,693 | 1.22 | 116.19% |
| 3 Years | 10.23 | 33.00 | 0.542 | 13.33 | 671,122 | -7.96 | -77.81% |
| 5 Years | 14.54 | 33.00 | 0.542 | 13.33 | 459,136 | -12.27 | -84.39% |
BeyondSpring Description
| BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. |
